에스디생명공학 217480

http://comp.fnguide.com/SVO2/asp/SVD_Main.asp?pGB=1&gicode=A217480&cID=&MenuYn=Y&ReportGB=&NewMenuID=101&stkGb=701 

에스디생명공학(A217480) | Snapshot | 기업정보 | Company Guide

- 다변화를 꿈꾸는 마스크팩의 강자 Not Rated 현재가  (9/18, 원) 13,250 - KB증권 - 2018.09.19
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=493858
- 기저효과 + 중국 내 마스크팩 반등 매수 (유지) 주가 (5/ 25 ) 16,300 원 TP 22,000 원 (유지)
  상승여력 35.0% - 신한투자 - 2018.05.29
   http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=479291
- 中 매출 성장 기대감 및 저평가 분석에 강세 18,800원 (+8.36%) - 2018.04.09
  ▷DB금융투자는 동사에 대해 중국 정식 유통채널을 통한 매출이 본격적으로 커지는 시기에 
  있으며, 북미와 유럽, 동남아로도 매출이 발생하는 첫해이기 때문에 마스크팩 기업 중에서는 
  동사가 어닝 모멘텀이 가장 견조할 것으로 분석.
  ▷아울러 내년 기준 중소형 화장품 기업들이 받고 있는 시장 P/E가 20배를 넘어서고있는 
  현 장세에서 동사의 P/E는 12배이기 때문에 저평가되어 있는 성장주라고 밝힘
- 쉬어가는 1분기 매수 (유지) 주가 (3 월 29 일) 18,300 원 목표주가 22,000 원 (유지) 
  상승여력 20.2% - 신한투자 - 2018.03.30
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=470315
- 새롭게 떠오르는 프리미엄 마스크팩 Not Rated 현재주가 (3.9) 17,700 원 - 
  메리츠증권 - 2018.03.12 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=468079
- 성장 가능성을 확인했다 Buy (Initiate) 목표주가 (12M) 20,000원 종가 (2018/03/05) 16,100원 -
  하이투자 - 2018.03.06
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=467345
- 이미 시작된 턴어라운드 매수 (유지) 주가 (2 월 26 일) 18,400 원 목표주가 22,000 원 (상향)
  상승여력 19.6% - 신한투자 - 2018.02.28 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=466761
- 기대 이하의 실적, 포기는 이르다 Not rated 주가(2/22) 18,600 - 한국투자 - 2018.02.23 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=466187
- 강력한 턴어라운드! Not rated 주가(1/26) 21,000 - 한국투자 - 2018.01.29 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=462157
- 한 발 빠른 턴어라운드 Not Rated - SK증권 - 2018.01.17
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=460368
- 해외 성장 본격화 전망에 급등 15,850원 (+12.81%) - 2018.01.09
  ▷BNK투자증권은 동사에 대해 올해 해외 성장이 본격화될 것으로 전망.
  인도네시아 AG그룹의 전문 화장품 계열사와 합작투자법인(J/V)을 설립계약을 체결하면서 
  상반기부터 AG그룹의 유통인프라를 활용해 판매를 개시할 예정이라고 밝힘.
  또한, 추후 자체 브랜드 출시 및 생산시설 구축까지 진행될 것이며 하반기에는 미국과 러시아 등 
  추가적인 수출 확대가 본격화 될것으로 전망.
  ▷투자의견 : 매수[유지], 목표주가 : 17,000원 → 19,000원[상향]
- 마스크팩의 숨겨진 작은 강자 Not Rated 현재주가 (1.5) 14,450원 - 메리츠증권 - 2018.01.08 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=458886
- 사드 완화 수혜주 매수 (신규) 주가 (12 월 20 일) 13,850 원 목표주가 18,000 원 (신규) 
  상승여력 30.0% - 신한투자 - 2017.12.22
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=457436
- 실적 턴어라운드 시점 도래 주가 (12/08) 12,200원 Not Rated  - 유안타증권 -2017.12.12
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=456355
- 사드와 성장통, 마스크팩 경쟁력 유지가 관전 포인트 Not Rated  - 한국투자 - 2017.12.01 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=454983

- 영업 현황 및 향후 전략 점검 Not Rated - 이베스트증권 - 2017.06.28
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=432691
- 고성장세 지속 예상 - 신한투자 -2017.06.21 
http://bbs2.shinhaninvest.com/siw/board/message/view.file.pop.do?boardName=gicompanyanalyst&messageId=765850